Gentium (GENT -4.3%) trades lower today after saying it expects to submit answers for its lead...

|About: Gentium S.p.A. ADR (GENTY)|By:, SA News Editor

Gentium (GENT -4.3%) trades lower today after saying it expects to submit answers for its lead product candidate Defibrotide to European regulators during Q1 of 2012. The drug is used to treat and prevent hepatic veno-occlusive disease in adults and children undergoing haematopoietic stem-cell transplantation therapy.